Jin-Hui Zhu

Dr. Jin-Hui Zhu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
JZJin-Hui Zhu
Jin-Hui Zhu
RMRamon Andrade De Mello
Ramon Andrade De Mello
QYQiu-Liang Yan
Qiu-Liang Yan
JWJian-Wei Wang
Jian-Wei Wang
YCYan Chen
Yan Chen
Tao HuangTao Huang
Tao Huang

16 April 2018 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
JZJin-Hui Zhu
Jin-Hui Zhu
YCYan Chen
Yan Chen
YJYun Ji
Yun Ji
YYYuanquan Yu
Yuanquan Yu
YJYun Jin
Yun Jin
JZJiale Zhou
Jiale Zhou

29 April 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
QYQiuliang Yan
Qiuliang Yan
DHDandan Hu
Dandan Hu
MLMaolan Li
Maolan Li
YCYan Chen
Yan Chen
XWXiangsong Wu
Xiangsong Wu
JZJin-Hui Zhu
Jin-Hui Zhu
Pancreatic cancer (PC) has high morbidity and mortality. It is the fourth leading cause of cancer death. Its diagnosis and treatment are difficult. Liquid biopsy makes early diagnosis of pancreatic cancer possible. We analyzed the expression profiles of 2,555 serum miRNAs in 100 pancreatic cancer patients and 150 healthy controls. With advanced feature selection methods, we identified 13 pancreatic cancer signature miRNAs that can classify the pancreatic cancer patients and healthy controls. For pancreatic cancer treatment, operation is still the first choice. But many pancreatic cancer patients are already inoperable. Therefore, we compared the 79 inoperable and 21 operable patients and identified 432 miRNAs that can predict whether a pancreatic cancer patient was operable. The functional analysis of the 13 pancreatic cancer signatures and the 432 operability miRNAs revealed the molecular mechanisms of pancreatic cancer and shield light on the diagnosis and therapy of pancreatic cancer in clinical practice.

15 October 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
JZJin-Hui Zhu
Jin-Hui Zhu
QYQiu-Liang Yan
Qiu-Liang Yan
JWJian-Wei Wang
Jian-Wei Wang
YCYan Chen
Yan Chen
QYQing-Huang Ye
Qing-Huang Ye
Tao HuangTao Huang
Tao Huang
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive form of pancreatic cancer. Its 5-year survival rate is only 3–5%. Perineural invasion (PNI) is a process of cancer cells invading the surrounding nerves and perineural spaces. It is considered to be associated with the poor prognosis of PDAC. About 90% of pancreatic cancer patients have PNI. The high incidence of PNI in pancreatic cancer limits radical resection and promotes local recurrence, which negatively affects life quality and survival time of the patients with pancreatic cancer. Objectives: To investigate the mechanism of PNI in pancreatic cancer, we analyzed the gene expression profiles of tumors and adjacent tissues from 50 PDAC patients which included 28 patients with perineural invasion and 22 patients without perineural invasion. Method: Using Monte-Carlo feature selection and Incremental Feature Selection (IFS) method, we identified 26 key features within which 15 features were from tumor tissues and 11 features were from adjacent tissues. Results: Our results suggested that not only the tumor tissue, but also the adjacent tissue, was informative for perineural invasion prediction. The SVM classifier based on these 26 key features can predict perineural invasion accurately, with a high accuracy of 0.94 evaluated with leave-one-out cross validation (LOOCV). Conclusion: The in-depth biological analysis of key feature genes, such as TNFRSF14, XPO1, and ATF3, shed light on the understanding of perineural invasion in pancreatic ductal adenocarcinoma.

1 July 2020 in Journal of Laparoendoscopic & Advanced Surgical Techniques
Verified
Journal Article
Closed access
ZWZhijiang Wang
Zhijiang Wang
YXYouhon Xu
Youhon Xu
DHDandan Hu
Dandan Hu
XWXiangsong Wu
Xiangsong Wu
YCYan Chen
Yan Chen
JZJin-Hui Zhu
Jin-Hui Zhu
Background: Some reports assert that there is a risk that laparoscopy might worsen the prognosis of incidental gallbladder carcinoma (IGBC) after laparoscopic cholecystectomy (LC) compared with open reoperation. The purpose of this study was to evaluate whether the surgical approach influences outcomes in patients with IGBC after LC. Methods: We retrospectively reviewed the medical records of 106 patients diagnosed with IGBC who had undergone LC for benign gallbladder disease such as cholecystolithiasis at our hospital between April 2010 and February 2018. We included patients with incidentally diagnosed GBC after routine pathology: 45 patients (16 men and 29 women; age: 45–76 years [mean: 62.6 years]) who underwent laparoscopic surgery and 61 patients (24 men and 37 women; age: 51–82 years [mean: 62.6 years]) who underwent open surgery. We evaluated outcomes in each group regarding tumor stage and operative time, time of reoperation after first operation, blood loss volume, number of lymph nodes in pathological specimens, hospital stay, and complication and survival rates. Results: Reoperation time after first operation, number of lymph nodes in pathological specimens, and operative time showed no statistical significance between laparoscopy and open reoperation. During follow-up, 3-year survival between laparoscopy (48.89%) and open reoperation (42.62%) showed no statistical significance, but laparoscopy had better 1-year survival (95.56% versus 86.89%, laparoscopy versus open, respectively; not significant [NS] <0.01) and 5-year survival (44.44% versus 29.51%, laparoscopy versus open, respectively; NS <0.05). However, comparing laparoscopy versus open surgery, respectively, blood -loss volume (100 ± 25.4 mL versus 200 ± 45.6 mL; NS <0.01), hospital stay (3.5 ± 1.9 days versus 5.6 ± 2.7 days, NS <0.01), and complication rates (6.7% versus 13.1%; NS <0.01) were lower, indicating better recovery and better patient experience. Conclusions: Laparoscopic radical reoperation for IGBC after LC is a feasible, effective, and safe procedure and is associated with less bleeding, low morbidity, and shorter hospital stay.

22 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
XCXi Chen
Xi Chen
RFRuibiao Fu
Ruibiao Fu
QSQian Shao
Qian Shao
YCYan Chen
Yan Chen
QYQinghuang Ye
Qinghuang Ye
JZJin-Hui Zhu
Jin-Hui Zhu
Background and Objectives: Pancreatic cancer (PC) is one of the deadliest cancers worldwide although substantial advancement has been made in its comprehensive treatment. The development of artificial intelligence (AI) technology has allowed its clinical applications to expand remarkably in recent years. Diverse methods and algorithms are employed by AI to extrapolate new data from clinical records to aid in the treatment of PC. In this review, we will summarize AI’s use in several aspects of PC diagnosis and therapy, as well as its limits and potential future research avenues.Methods: We examine the most recent research on the use of AI in PC. The articles are categorized and examined according to the medical task of their algorithm. Two search engines, PubMed and Google Scholar, were used to screen the articles.Results: Overall, 66 papers published in 2001 and after were selected. Of the four medical tasks (risk assessment, diagnosis, treatment, and prognosis prediction), diagnosis was the most frequently researched, and retrospective single-center studies were the most prevalent. We found that the different medical tasks and algorithms included in the reviewed studies caused the performance of their models to vary greatly. Deep learning algorithms, on the other hand, produced excellent results in all of the subdivisions studied.Conclusions: AI is a promising tool for helping PC patients and may contribute to improved patient outcomes. The integration of humans and AI in clinical medicine is still in its infancy and requires the in-depth cooperation of multidisciplinary personnel.